Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd.
Clinical trials sponsored by Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd., explained in plain language.
-
New drug 610 aims to tame severe asthma attacks
Disease control Recruiting nowThis Phase 3 trial tests a new drug called 610 in 480 Chinese adults with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. Participants receive either 610 or a placebo injection for 52 weeks. The main goal is to see if 610 reduces t…
Phase: PHASE3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug 608 aims to ease back pain in ankylosing spondylitis
Disease control Recruiting nowThis Phase 3 trial tests an experimental drug called 608 in 500 adults with active ankylosing spondylitis (AS), a type of arthritis that causes back pain and stiffness. Participants receive either 608 injections or a placebo. The main goal is to see if 608 improves symptoms like …
Phase: PHASE3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New lupus drug candidate enters human trials
Disease control Recruiting nowThis study tests an experimental drug called SSGJ-626, an antibody that targets a protein on certain immune cells, in people with systemic lupus erythematosus (SLE). The trial will enroll 198 adults aged 18-70 with SLE. Participants will receive either the drug or a placebo as a …
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug 611 aims to cut COPD attacks in chinese patients
Disease control Recruiting nowThis Phase 3 trial tests whether the experimental drug 611 can reduce moderate to severe COPD flare-ups in Chinese adults aged 40-85 with moderate to severe COPD. About 594 participants will receive either 611 or a placebo injection every two weeks. The study measures how often f…
Phase: PHASE3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New shot could clear eczema in teens – trial underway
Disease control Recruiting nowThis Phase 3 trial tests a drug called 611 in 180 Chinese teenagers (ages 12–17) with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. Participants receive injections every two weeks for up to a year. The main go…
Phase: PHASE3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC